BT595, a 10% Human Normal Immunoglobulin, for Replacement Therapy of Primary Immunodeficiency Disease: Results of a Subcohort Analysis in Children

ConclusionBT595 is effective, convenient, well tolerated, and safe for the treatment of children with PID.Trial registrationEudraCT: 2015 –003652-52; NCT02810444, registered June 23, 2016.
Source: Journal of Clinical Immunology - Category: Allergy & Immunology Source Type: research